Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
By N. Muñoz, S. Kjaer, K. Sigurdsson, O. Iversen, M. Hernández-Ávila, C. Wheeler, Gonzalo Pérez, Darron R. Brown, L. Koutsky, E. Tay and 28 more. Journal of the National Cancer Institute, 2010
638 citations recorded by the source corpus.
Subfields: Epidemiology, Microbiology, Obstetrics and Gynecology
View Paper: https://www.semanticscholar.org/paper/bf617a07ed019127f82a2ee613d956b57f99bd63
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma (2023, positive): “Randomized trials for the Cervarix and Gardasil vaccines have also shown a significant reduction in cervical, vaginal, and vulvar HPV infection and HPV-associated precancerous lesions [65].”
- A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “8) [21], due to their relatively high incidence and relatively rapid progression from incident infection to clinical disease.”